Gongwin Biopharm Holdings
6617.TWO
3.02 USD
-0.04
-1.31%
g
Overview
Last close
3.02 usd
Market cap
342.03M usd
52 week high
6.84 usd
52 week low
2.85 usd
Target price
N/A usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
392.3183
Price/Book Value
4.0716
Enterprise Value
313.38M usd
EV/Revenue
324.1399
EV/EBITDA
-167.232
Key financials
Revenue TTM
958479.18 usd
Gross Profit TTM
542275.2 usd
EBITDA TTM
-4.35M usd
Earnings per Share
-0.02 usd
Dividend
N/A usd
Total assets
N/A usd
Net debt
N/A usd
About
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of liver cancer; PTS-02 for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company was founded in 2014 and is based in Taipei, Taiwan.
- Symbol6617.TWO
- ExchangeTWO
- IsinN/A
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CEO
- HeadquarterTaipei
- Web sitehttps://www.gongwinbiopharm.com
